CAR-T Treatment Continues to Astonish in Rheumatologic Diseases
Numbers of patients, length of follow-up keep growing with no visible downside (yet)
Source: medpagetoday.com
Stay updated with breaking news from Greg Deener. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Numbers of patients, length of follow-up keep growing with no visible downside (yet)
BCMA-CD19 compound CAR (cCAR) therapy was safe and well tolerated and achieved proof of concept of complete humoral reset delivering long-term medication-free remission - iCell's BCMA-CD19 cCAR